A recent study11 supported the premise that NPM1 mutations define AML regardless of the blast count, even if <10%, and that patients diagnosed with NPM1mut CMML actually have early-stage NPM1mut AML. This evidence concerns the gene NPM1 and chronic myelomonocytic leukemia.